PMN

ProMIS Neurosciences Inc.

PMN, USA

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

https://www.promisneurosciences.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PMN
stock
PMN

Tech stocks weigh on Canadian, U.S. markets while pot stocks surge Winnipeg Sun

Read more →
PMN
stock
PMN

ProMIS Neurosciences shareholders approve share consolidation proposal By Investing.com Investing.com Nigeria

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$222.2391

Analyst Picks

Strong Buy

2

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.36

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-126.04 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-53.97 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

1.34

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 17.54% of the total shares of ProMIS Neurosciences Inc.

1.

Great Point Partners LLC

(5.1058%)

since

2025/06/30

2.

Armistice Capital, LLC

(4.1267%)

since

2025/06/30

3.

Sphera Funds Management Ltd.

(3.6661%)

since

2025/06/30

4.

Ally Bridge Group (NY) LLC

(2.5758%)

since

2025/06/30

5.

Altium Capital Management, LP

(1.1084%)

since

2025/03/31

6.

Allostery Investments LP

(0.3006%)

since

2025/06/30

7.

Citadel Advisors Llc

(0.1224%)

since

2025/06/30

8.

JNB Advisors LLC

(0.102%)

since

2025/06/30

9.

Kingsview Wealth Management, LLC

(0.06%)

since

2025/06/30

10.

Bank of Montreal

(0.0586%)

since

2025/06/30

11.

BMO Capital Markets Corp.

(0.0586%)

since

2025/06/30

12.

Fiduciary Trust Co

(0.0552%)

since

2025/06/30

13.

Howard Financial Services Ltd

(0.0503%)

since

2025/06/30

14.

IEQ CAPITAL, LLC

(0.0503%)

since

2025/06/30

15.

Scotia Capital Inc

(0.0234%)

since

2025/06/30

16.

Commonwealth Equity Services Inc

(0.0221%)

since

2025/06/30

17.

Claret Asset Management Corporation

(0.0219%)

since

2025/06/30

18.

Fidelity Nasdaq Composite Index

(0.0166%)

since

2025/07/31

19.

Royal Bank of Canada

(0.0106%)

since

2025/06/30

20.

Bank of America Corp

(0.0032%)

since

2025/06/30

21.

TD Waterhouse Canada Inc

(0.0003%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

-0.205

Latest Release

Date

2025-09-30

EPS Actual

-0.24

EPS Estimate

-0.24

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.